Land: Armenië
Taal: Engels
Bron: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
influenza vaccine inactivated (surface antigen)-A/Brisbane/02/2018 (H1N1) pdm-like strain (A/Brisbane/02/2018, IVR-190), A/Kansas/14/2017 (H3N2)-like strain (A/ A/Kansas/14/2017, NYMC X-327), B/Colorado/06/2017-like strain (B/ Victoria/2/87/ lineage) (B/Maryland/15/2016, NYMC BX-69 A)
ABBOTT Biologicals B.V. Veerweg 12
J07BB02
influenza vaccine inactivated (surface antigen)-A/Brisbane/02/2018 (H1N1) pdm-like strain (A/Brisbane/02/2018, IVR-190), A/Kansas/14/2017 (H3N2)-like strain (A/ A/Kansas/14/2017, NYMC X-327), B/Colorado/06/2017-like strain (B/ Victoria/2/87/ lineage) (B/Maryland/15/2016, NYMC BX-69 A)
15mcg haemagglutinin/dose+ 15mcg haemagglutinin/dose+ 15mcg haemagglutinin/dose
suspension for injection
(1) pre-filled syringe 0,5ml
Prescription
Registered
2019-10-11
SUMMARY OF PRODUCT CHARACTERISTIC 1/5 1. NAME OF THE MEDICAL PRODUCT Influvac 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains*: - A/Brisbane/02/2018 (H1N1)pdm09-like strain (A/Brisbane/02/2018, IVR-190)………………………………,,,,,,,,,,,…...15 micrograms HA** - A/Kansas/14/2017 (H3N2)-like strain (A/Kansas/14/2017, NYMC X-327)……………………,,,,,,,,,,,,,,,,,,,,……15 micrograms HA** - B/Colorado/06/2017-like strain (B/Maryland/15/2016, NYMC BX-69A)………………………………….15 micrograms HA** per 0.5 ml dose *propagated in fertilised hens’ eggs from healthy chicken flocks **haemagglutinin This vaccine complies with the World Health Organisation (WHO) recommendation (northern hemisphere) and competent authority decision for the 2019/2020 season. For a full list of excipients see section 5.1. Influvac 2019/2020 may contain traces of eggs (such as ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80 or gentamicin, which are used during the manufacturing process (see section 3.3). 3. PHARMACEUTICAL FORM Suspension for injection in prefilled syringes; a colourless clear liquid, filled in single-dose syringes (glass, Type I). 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of influenza is indicated in adults and children from 6 months of age; especially those who run an increased risk of associated complications. Vaccination is particularly recommended for the following categories of patients, depending on national immunization policies: • Persons aged ≥ 65 years, regardless their health condition. • Adults and children with chronic disorders of the pulmonary or cardiovascular systems, including asthma. • Adults and children with chronic metabolic diseases such as diabetes mellitus. • Adults and children with chronic renal dysfunction. • Adults and children with immunodeficiencies due to disease or immunosuppressant medication Lees het volledige document